A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases

Andrew L Feldman, H. Richard Alexander, David L. Bartlett, Karen C. Kranda, Marshall S. Miller, Nick G. Costouros, Peter L. Choyke, Steven K. Libutti

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: Circulating inhibitors of angiogenesis have been suggested to affect the growth of distant micrometastatic disease in patients with cancer. This study was designed to evaluate circulating endostatin levels in colorectal cancer patients with liver metastases. Methods: Plasma samples from 30 colorectal cancer patients with liver metastases were analyzed for endostatin and vascular endothelial growth factor (VEGF) by using competitive enzyme immunoassays. Samples were compared with plasma from age- and sex-matched healthy controls; values >2 SD above the control mean were considered elevated. Results: Plasma endostatin levels were significantly higher in the 30 cancer patients than controls (P < .0001) and correlated with preoperative VEGF levels (P = .0008). Eighteen patients underwent surgical treatment (liver resection, n = 10; or isolated hepatic perfusion with melphalan, n = 8). Seventeen treated patients were available for follow-up. Eight of 11 patients who progressed had elevated plasma endostatin levels at the time of progression. None of six patients who remained progression free had elevated endostatin levels at last follow-up (P = .02). Conclusions: Plasma endostatin levels are elevated in colorectal cancer patients with liver metastases and correlate with VEGF levels. Elevated endostatin levels during follow-up are associated with disease progression. Understanding the role of endogenous endostatin in cancer patients may lead to novel strategies to inhibit tumor angiogenesis.

Original languageEnglish (US)
Pages (from-to)741-745
Number of pages5
JournalAnnals of Surgical Oncology
Volume8
Issue number9
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Endostatins
Colorectal Neoplasms
Neoplasm Metastasis
Liver
Vascular Endothelial Growth Factor A
Neoplasms
Melphalan
Angiogenesis Inhibitors
Immunoenzyme Techniques
Disease Progression
Perfusion

Keywords

  • Angiogenesis
  • Colorectal cancer
  • Endostatin
  • Liver metastasis
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Feldman, A. L., Alexander, H. R., Bartlett, D. L., Kranda, K. C., Miller, M. S., Costouros, N. G., ... Libutti, S. K. (2001). A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Annals of Surgical Oncology, 8(9), 741-745. https://doi.org/10.1245/aso.2001.8.9.741

A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. / Feldman, Andrew L; Alexander, H. Richard; Bartlett, David L.; Kranda, Karen C.; Miller, Marshall S.; Costouros, Nick G.; Choyke, Peter L.; Libutti, Steven K.

In: Annals of Surgical Oncology, Vol. 8, No. 9, 2001, p. 741-745.

Research output: Contribution to journalArticle

Feldman, AL, Alexander, HR, Bartlett, DL, Kranda, KC, Miller, MS, Costouros, NG, Choyke, PL & Libutti, SK 2001, 'A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases', Annals of Surgical Oncology, vol. 8, no. 9, pp. 741-745. https://doi.org/10.1245/aso.2001.8.9.741
Feldman, Andrew L ; Alexander, H. Richard ; Bartlett, David L. ; Kranda, Karen C. ; Miller, Marshall S. ; Costouros, Nick G. ; Choyke, Peter L. ; Libutti, Steven K. / A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. In: Annals of Surgical Oncology. 2001 ; Vol. 8, No. 9. pp. 741-745.
@article{05a20caf7ffb4f7a809d78315d6d85f3,
title = "A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases",
abstract = "Background: Circulating inhibitors of angiogenesis have been suggested to affect the growth of distant micrometastatic disease in patients with cancer. This study was designed to evaluate circulating endostatin levels in colorectal cancer patients with liver metastases. Methods: Plasma samples from 30 colorectal cancer patients with liver metastases were analyzed for endostatin and vascular endothelial growth factor (VEGF) by using competitive enzyme immunoassays. Samples were compared with plasma from age- and sex-matched healthy controls; values >2 SD above the control mean were considered elevated. Results: Plasma endostatin levels were significantly higher in the 30 cancer patients than controls (P < .0001) and correlated with preoperative VEGF levels (P = .0008). Eighteen patients underwent surgical treatment (liver resection, n = 10; or isolated hepatic perfusion with melphalan, n = 8). Seventeen treated patients were available for follow-up. Eight of 11 patients who progressed had elevated plasma endostatin levels at the time of progression. None of six patients who remained progression free had elevated endostatin levels at last follow-up (P = .02). Conclusions: Plasma endostatin levels are elevated in colorectal cancer patients with liver metastases and correlate with VEGF levels. Elevated endostatin levels during follow-up are associated with disease progression. Understanding the role of endogenous endostatin in cancer patients may lead to novel strategies to inhibit tumor angiogenesis.",
keywords = "Angiogenesis, Colorectal cancer, Endostatin, Liver metastasis, Vascular endothelial growth factor",
author = "Feldman, {Andrew L} and Alexander, {H. Richard} and Bartlett, {David L.} and Kranda, {Karen C.} and Miller, {Marshall S.} and Costouros, {Nick G.} and Choyke, {Peter L.} and Libutti, {Steven K.}",
year = "2001",
doi = "10.1245/aso.2001.8.9.741",
language = "English (US)",
volume = "8",
pages = "741--745",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases

AU - Feldman, Andrew L

AU - Alexander, H. Richard

AU - Bartlett, David L.

AU - Kranda, Karen C.

AU - Miller, Marshall S.

AU - Costouros, Nick G.

AU - Choyke, Peter L.

AU - Libutti, Steven K.

PY - 2001

Y1 - 2001

N2 - Background: Circulating inhibitors of angiogenesis have been suggested to affect the growth of distant micrometastatic disease in patients with cancer. This study was designed to evaluate circulating endostatin levels in colorectal cancer patients with liver metastases. Methods: Plasma samples from 30 colorectal cancer patients with liver metastases were analyzed for endostatin and vascular endothelial growth factor (VEGF) by using competitive enzyme immunoassays. Samples were compared with plasma from age- and sex-matched healthy controls; values >2 SD above the control mean were considered elevated. Results: Plasma endostatin levels were significantly higher in the 30 cancer patients than controls (P < .0001) and correlated with preoperative VEGF levels (P = .0008). Eighteen patients underwent surgical treatment (liver resection, n = 10; or isolated hepatic perfusion with melphalan, n = 8). Seventeen treated patients were available for follow-up. Eight of 11 patients who progressed had elevated plasma endostatin levels at the time of progression. None of six patients who remained progression free had elevated endostatin levels at last follow-up (P = .02). Conclusions: Plasma endostatin levels are elevated in colorectal cancer patients with liver metastases and correlate with VEGF levels. Elevated endostatin levels during follow-up are associated with disease progression. Understanding the role of endogenous endostatin in cancer patients may lead to novel strategies to inhibit tumor angiogenesis.

AB - Background: Circulating inhibitors of angiogenesis have been suggested to affect the growth of distant micrometastatic disease in patients with cancer. This study was designed to evaluate circulating endostatin levels in colorectal cancer patients with liver metastases. Methods: Plasma samples from 30 colorectal cancer patients with liver metastases were analyzed for endostatin and vascular endothelial growth factor (VEGF) by using competitive enzyme immunoassays. Samples were compared with plasma from age- and sex-matched healthy controls; values >2 SD above the control mean were considered elevated. Results: Plasma endostatin levels were significantly higher in the 30 cancer patients than controls (P < .0001) and correlated with preoperative VEGF levels (P = .0008). Eighteen patients underwent surgical treatment (liver resection, n = 10; or isolated hepatic perfusion with melphalan, n = 8). Seventeen treated patients were available for follow-up. Eight of 11 patients who progressed had elevated plasma endostatin levels at the time of progression. None of six patients who remained progression free had elevated endostatin levels at last follow-up (P = .02). Conclusions: Plasma endostatin levels are elevated in colorectal cancer patients with liver metastases and correlate with VEGF levels. Elevated endostatin levels during follow-up are associated with disease progression. Understanding the role of endogenous endostatin in cancer patients may lead to novel strategies to inhibit tumor angiogenesis.

KW - Angiogenesis

KW - Colorectal cancer

KW - Endostatin

KW - Liver metastasis

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0034794547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034794547&partnerID=8YFLogxK

U2 - 10.1245/aso.2001.8.9.741

DO - 10.1245/aso.2001.8.9.741

M3 - Article

C2 - 11597016

AN - SCOPUS:0034794547

VL - 8

SP - 741

EP - 745

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 9

ER -